The Acceptability of Pre-Exposure Prophylaxis: Beliefs of Health-Care Professionals Working in Sexually Transmitted Infections Clinics and HIV Treatment Centers

Janneke P. Bil1†, Elske Hoornenborg1,2*, Maria Prins1,3, Arjan Hogewoning2,4, Fernando Dias Goncalves Lima1, Henry J. C. de Vries2,3,4,5 and Udi Davidovich1

1Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Netherlands, 2Department of Infectious Diseases, STI Outpatient Clinic, Public Health Service of Amsterdam, Amsterdam, Netherlands, 3Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 5Center for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, Netherlands

Background: Pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV infections, but is not yet implemented in the Netherlands. As the attitudes of health-care professionals toward PrEP can influence future PrEP implementation, we studied PrEP knowledge and beliefs and their association with PrEP acceptability among professionals in clinics for sexually transmitted infection (STI professionals) and HIV treatment centers (HIV specialists). In addition, we examined preferred regimens, attitudes toward providing PrEP to key populations and to reimbursement of PrEP costs.

Methods: An online questionnaire was distributed among 24 public health STI clinics and 27 HIV treatment centers nationwide in the Netherlands between January and August 2015. The acceptability of PrEP was measured on a 7-point Likert scale ranging from 1 = low to 7 = high acceptability. Univariable and multivariable linear regression analyses were used to explore associations between demographic characteristics, PrEP knowledge, beliefs about PrEP, and PrEP acceptability.

Results: In total, 209 people (143 STI professionals and 66 HIV specialists) completed the questionnaire. The mean acceptability of PrEP implementation was 4.28 (SD 1.68) among STI professionals and 4.42 (SD 1.67) among HIV specialists. The mean score on self-perceived knowledge related to PrEP efficacy was 3.90 (SD 1.57) among STI professionals and 5.68 (SD 1.08) among HIV specialists (p-value of <0.001). Beliefs associated with lower PrEP acceptability among both groups were the fear that PrEP use will lead to a decrease in condom use and an increase in STI, the high costs of PrEP and ethical issues regarding prescribing antiretroviral medication to healthy individuals. No preference for a daily or an event-driven regimen was detected. Most participants deemed the following groups to be eligible for PrEP: men who have sex with men (MSM)
Pre-exposure prophylaxis (PrEP) entails offering a regime of lower-intensity antiretroviral therapy (ART) to HIV-negative individuals to reduce their risk of HIV infection. PrEP is offered in combination with other behavioral interventions such as condom use, counseling on sexual-risk behavior, frequent HIV testing, and linkage to other HIV prevention services (1–3). Several studies have demonstrated that both daily and event-driven PrEP regimens are highly effective (4–7), and the current guidelines of a number of international organizations include PrEP as a prevention strategy for key populations. In the developed world, HIV spreads most rapidly in men who have sex with men (MSM) (1, 8). A modeling study based on Dutch data estimated that 30% (range: 22–39%) of new HIV infections could have been averted if half of all MSM under 30 had received PrEP in combination with immediate ART for those who test positive (9). In addition, PrEP implementation was estimated to be cost-effective in the Netherlands over a 30-year time frame if PrEP was provided to the 10% most sexually active MSM (10). Despite these results and the July 2016 approval of Truvada (emtricitabine/tenofovir disoproxil) for PrEP in the European Union, PrEP is not yet routinely available or reimbursed in the Netherlands.

For the effective implementation of PrEP, it is important to understand health-care professionals’ level of knowledge and beliefs or concerns about PrEP, as they will play a critical role in its implementation. The acceptability of PrEP among health-care professionals at clinics for sexually transmitted infections (STIs) and HIV treatment centers is of particular importance as PrEP is most likely to be implemented at these facilities, due to their experience in offering prevention services to individuals at risk for HIV and experience in providing HIV treatment, respectively.

In this cross-sectional study among professionals working at STI clinics (STI professionals) and at HIV treatment centers (HIV specialists) in the Netherlands, we aimed to gain insight into the acceptability of PrEP, prescription setting, potential determinants of PrEP acceptability (such as knowledge and beliefs about PrEP), and preferred PrEP regimens. We examined attitudes toward providing PrEP to key populations and toward the reimbursement of PrEP costs. The resulting insights will guide future PrEP implementation strategies and help design PrEP educational programs for professionals.

**INTRODUCTION**

Pre-exposure prophylaxis (PrEP) entails offering a regime of lower-intensity antiretroviral therapy (ART) to HIV-negative individuals to reduce their risk of HIV infection. PrEP is offered in combination with other behavioral interventions such as condom use, counseling on sexual-risk behavior, frequent HIV testing, and linkage to other HIV prevention services (1–3). Several studies have demonstrated that both daily and event-driven PrEP regimens are highly effective (4–7), and the current guidelines of a number of international organizations include PrEP as a prevention strategy for key populations. In the developed world, HIV spreads most rapidly in men who have sex with men (MSM) (1, 8). A modeling study based on Dutch data estimated that 30% (range: 22–39%) of new HIV infections could have been averted if half of all MSM under 30 had received PrEP in combination with immediate ART for those who test positive (9). In addition, PrEP implementation was estimated to be cost-effective in the Netherlands over a 30-year time frame if PrEP was provided to the 10% most sexually active MSM (10). Despite these results and the July 2016 approval of Truvada (emtricitabine/tenofovir disoproxil) for PrEP in the European Union, PrEP is not yet routinely available or reimbursed in the Netherlands.

For the effective implementation of PrEP, it is important to understand health-care professionals’ level of knowledge and beliefs or concerns about PrEP, as they will play a critical role in its implementation. The acceptability of PrEP among health-care professionals at clinics for sexually transmitted infections (STIs) and HIV treatment centers is of particular importance as PrEP is most likely to be implemented at these facilities, due to their experience in offering prevention services to individuals at risk for HIV and experience in providing HIV treatment, respectively.

In this cross-sectional study among professionals working at STI clinics (STI professionals) and at HIV treatment centers (HIV specialists) in the Netherlands, we aimed to gain insight into the acceptability of PrEP, prescription setting, potential determinants of PrEP acceptability (such as knowledge and beliefs about PrEP), and preferred PrEP regimens. We examined attitudes toward providing PrEP to key populations and toward the reimbursement of PrEP costs. The resulting insights will guide future PrEP implementation strategies and help design PrEP educational programs for professionals.
and administrative workers), the location of STI clinic (large urban area/outside of large urban area) or the type of hospital (academic or general), and the length of employment in STI clinic/hospital. HIV specialists were additionally asked for the number of HIV-positive patients at their clinic. Experience with PrEP was measured by asking whether participants had received questions about PrEP from clients/patients in the previous 6 months. HIV specialists were additionally asked whether they had ever prescribed PrEP.

**PrEP Acceptability**

Pre-exposure prophylaxis acceptability was measured via several items on a 7-point scale ranging from 1 “completely disagree” to 7 “completely agree.” The acceptability of PrEP implementation in the Netherlands was measured by one central item: “If PrEP is registered (i.e., granted market authorization), it should be implemented in the Netherlands as a new HIV intervention strategy.” In addition, among STI professionals, we also measured the acceptability of implementation at STI clinics by the item: “If PrEP is registered, it should be prescribed at STI clinics.” Among HIV specialists, we additionally measured acceptability toward implementation at HIV treatment centers and at general practitioners’ offices by the items: “If PrEP is registered, it should be prescribed by HIV specialists,” and “If PrEP is registered, it should be prescribed by general practitioners.” Moreover, we queried their willingness to prescribe through the item: “If PrEP is registered, I would be willing to prescribe PrEP.”

**Self-Perceived Knowledge of PrEP**

For all participants (except where indicated in parentheses), the following self-perceived items were measured on a 7-point Likert scale ranging from 1 “very poor” to 7 “very good”: knowledge of PrEP efficacy and the frequency/severity of side effects, the efficacy to inform patients about PrEP (only among STI professionals), the ability to identify key populations for PrEP use (only among HIV specialists), and the capability of deciding to prescribe PrEP (only among HIV specialists). Self-perceived knowledge about the frequency and severity of side effects was combined in one item in the analysis (self-perceived knowledge about side effects) as it was highly correlated (Spearman’s rho >0.9; \( p < 0.001 \)).

**Beliefs about PrEP**

Based on the focus group discussions, general beliefs about PrEP were measured with 50 items among STI professionals and 15 items among HIV specialists (Table S1 in Supplementary Material). For analyses, items were combined if they measured the same belief and had acceptable correlation (two items: Spearman’s rho ≥0.6 and \( p < 0.05 \); more than two items: Cronbach’s alpha ≥0.7). As the data collection of general beliefs differed between STI professionals (where all beliefs from the focus group discussions were measured) and HIV specialists (where only the selected major themes from the focus group discussions were measured), these correlation analyses were done separately for STI professionals and HIV specialists, and no comparisons were performed between the groups regarding beliefs. This resulted in 16 general beliefs about PrEP in the questionnaire for STI professionals and eight in the questionnaire for HIV specialists.

All general beliefs were measured on a 7-point scale ranging from 1 “completely disagree” to 7 “completely agree.”

Among STI professionals, we additionally measured one belief about PrEP efficacy (ranging from “PrEP can reduce the risk of HIV by 100%” to “Although PrEP reduces the risk of HIV, there is still a great risk of HIV transmission”): one belief about the frequency of side effects (side effects are rare/are sometimes reported/appear frequently/knowledge is still scarce/I don’t know) and one belief about the severity of side effects (side effects are often severe/are often mild or non-severe/knowledge is still scarce/I don’t know).

**Daily versus Event-Driven PrEP Use**

Beliefs about daily versus event-driven PrEP were measured with seven items in both questionnaires, using a 7-point scale ranging from 1 “completely disagree” to 7 “completely agree” (see Table S2 in Supplementary Material for more details). Given the good correlation between items (Cronbach’s alpha of 0.81 for STI professionals and 0.77 for HIV specialists), all seven items were combined.

**Key Populations, Reimbursement of PrEP Costs, and Serodiscordant Couples**

Questions were asked about the perceived PrEP eligibility of key groups (MSM, heterosexuals, and commercial sex workers) within different behavioral scenarios (e.g., condom use, repeatedly having an STI, having an HIV-positive partner, and repeatedly using post-exposure prophylaxis). For each scenario, participants were asked to assess eligibility by choosing one of the following options: not eligible/possibly eligible/eligible. Participants were also asked who should pay for PrEP (PrEP user/health insurance/government/partially PrEP users and partially health insurance or government/neutral).

HIV specialists were asked what intervention they prefer to prevent HIV transmission in serodiscordant couples (only ART for the HIV-positive partner/only PrEP for the HIV-negative partner/ART for the HIV-positive partner and PrEP for the HIV-negative partner as a transition phase until the HIV-positive partner has an undetectable viral load/only counseling).

**Statistical Analyses**

We described demographic characteristics, PrEP experience and knowledge, general beliefs about PrEP and about event-driven versus daily use, key populations, reimbursement of costs, and preferred interventions for serodiscordant couples. We compared distributions of acceptability and knowledge by the type of health-care provider (nurse/physician/other profession) and between STI professionals and HIV specialists, using Student’s \( t \)-tests and one-way ANOVA for normally distributed continuous variables and Mann–Whitney \( U \)-tests and Kruskal–Wallis tests for not-normally distributed continuous variables. Because of the differences in how the general beliefs were constructed among STI professionals and HIV specialists, a direct comparison between the general beliefs between STI clinic professionals and HIV specialists was not possible.

We performed univariable and multivariable linear regression analyses to explore associations between demographic
characteristics, PrEP knowledge, PrEP beliefs, and the acceptability of PrEP implementation in the Netherlands. A multivariable model was built using backward techniques. First, variables on PrEP knowledge and beliefs with a \( p \)-value of <0.10 in univariable analyses were entered into the model. Second, also demographic determinants with a \( p \) of <0.10 in univariable analyses were entered into the model. A \( p \)-value of \( \leq 0.05 \) was considered to be statistically significant. Interactions between the variables in the final model were checked. As the data collection differed between STI professionals and HIV specialists, analyses were done separately for STI professionals and HIV specialists. Analyses were performed using STATA Intercooled 13.1 (STATA Corporation, College Station, TX, USA).

RESULTS

Demographic Characteristics and PrEP Experience

All of the 24 STI clinics we contacted agreed to participate in the study (Figure 1). In the nine STI clinics that provided data on the number of questionnaires distributed, the response rate was 54.4% (104/191). In total, 143 STI professionals completed the questionnaire (Table 1): 93 nurses, 37 physicians, and 13 other professionals. A majority of respondents (113/143, 79.0%) were female; about half worked in an STI clinic in a large urban area (65/143, 45.5%) and most (95/143, 66.4%) had worked for more than 4 years in an STI clinic. About half (69/143, 48.3%) had received questions about PrEP from clients in the preceding 6 months but only 4.3% (3/69) were queried at least once a week.

Of 170 HIV specialists invited to participate, 66 (38.8%) completed the questionnaire, including 40 nurses and 26 physicians (Table 1). Most HIV specialists were female (39/66, 59.1%); half (34/66, 51.5%) worked in an academic hospital and 84.8% (56/66) had more than 4 years of experience. Of these specialists, 83.3% (55/66) had received patient questions about PrEP in the preceding 6 months and 7.6% (5/66) had ever prescribed PrEP.

PrEP Acceptability

Among STI professionals and HIV specialists, the mean score on the acceptability of PrEP implementation in the Netherlands was 4.28 (SD 1.68) and 4.42 (SD 1.67), respectively (Table 2). The mean acceptability score of PrEP implementation at STI clinics was 4.16 (SD 1.86) among STI professionals and 4.48 (SD 1.83) among HIV specialists. Among the latter, the mean acceptability score for implementation at HIV treatment centers was 3.91 (SD 1.97) and 2.45 (SD 1.82) for implementation at general practitioners’ offices. Their mean score for the willingness to prescribe PrEP was 4.39 (SD 1.89).

Self-Perceived Knowledge of PrEP

Among STI professionals, the mean score on self-perceived knowledge was 3.90 (SD 1.57) for PrEP efficacy and 2.84 (SD 1.39) for PrEP side effects; the mean score on self-perceived efficacy to inform clients about PrEP was 2.89 (SD 1.44) (Table 2). The mean score on self-perceived knowledge among HIV specialists was 5.68 (SD 1.08) for PrEP efficacy and 5.61 (SD 1.34) for side effects; it was 5.02 (SD 1.33) for self-perceived efficacy to identify key groups and 4.61 (SD 1.40) for the decision to prescribe PrEP. Self-perceived knowledge of efficacy (\( z = -7.46, p < 0.001 \)) and side effects (\( z = -9.60, p < 0.001 \)) was significantly higher among HIV specialists compared to that among STI professionals.

Beliefs about PrEP

Among STI professionals, the three general beliefs with the strongest agreement scores were (Table 2) “it is unclear who will have to pay for PrEP” (mean 5.52, SD 1.51), “taking PrEP is better than getting HIV” (mean 5.27, SD 1.49), and “adherence to PrEP will be insufficient” (mean 5.25, SD 1.41). Among HIV specialists, the three general beliefs with the highest agreement scores were “the use of PrEP will lead to a decrease in condom use and an increase in STI” (mean 5.13, SD 1.34), “I’m worried about long-term side effects of PrEP” (mean 4.89, SD 1.51), and “it is unethical to prescribe ART to healthy individuals” (mean 4.64, SD 1.72).

---

**FIGURE 1** | Flowchart of recruitment procedures of STI professionals working at STI clinics of the Public Health Service and HIV specialists working at HIV treatment centers, the Netherlands, 2015. (a) Total number of persons invited by contact persons is unknown. (b) Response rate was 54% (104/191) among nine clinics that provided data on the number of questionnaires distributed. STI, sexually transmitted infection.
Determinants of PrEP Acceptability

In the final multivariable analyses among STI professionals (Table 3), the following beliefs were associated with a higher acceptability of PrEP implementation in the Netherlands: “taking PrEP is better than getting HIV” (β = 0.15, p = 0.020), “PrEP is an effective intervention to prevent HIV” (β = 0.45, p < 0.001), and “PrEP prescription should be part of routine care at STI clinics” (β = 0.17, p = 0.013). Beliefs associated with a lower PrEP acceptability among STI professionals were “the use of PrEP will lead to a decrease in condom use and increase in STI” (β = −0.21, p = 0.034) and “the costs of PrEP are a problem” (β = −0.28, p = 0.019).

In the final multivariable analyses among HIV specialists (Table 4), physicians were less likely to have a positive attitude toward PrEP implementation than nurses (β = −0.83, p = 0.008). Beliefs associated with a higher PrEP acceptability among all HIV specialists were “PrEP is an effective intervention to prevent HIV” (β = 0.49, p = 0.023) and “PrEP is a good addition to prevention strategies” (β = 0.28, p = 0.040). The belief associated with a lower PrEP acceptability was “it is unethical to prescribe ART to healthy individuals” (β = −0.31, p = 0.005).

Daily versus Event-Driven PrEP Use

There was no preference for daily or event-driven PrEP, given the mean score of the combined beliefs about event-driven versus daily PrEP of 3.99 (SD 1.00) among STI professionals and 4.14 (SD 1.01) among HIV specialists (Table S2 in Supplementary Material).
TABLE 2 | Knowledge and beliefs about PrEP among 209 health-care professionals, the Netherlands (2015).

| STI professionals | HIV specialists | STI professionals versus HIV specialists |
|-------------------|-----------------|------------------------------------------|
|                   | Total (N = 143) | Nurse (n = 93) | Physician (n = 37) | Other (n = 13) | STI nurse versus STI physician versus STI other | Total (N = 66) | Nurse (n = 40) | Physician (n = 26) | HIV nurse versus HIV physician |
|                   | Mean  | SD    | Mean  | SD    | Mean  | SD    | Mean  | SD    | Mean  | SD    | Mean  | SD    | Mean  | SD    | Mean  | SD    |
| PreP acceptability (7-point scale: 1 "completely disagree" to 7 "completely agree") | | | | | | | | | | | | | | | |
| If PrEP is registered, it should be implemented in the Netherlands as a new HIV intervention strategy | 4.28  | 1.68  | 4.20  | 1.56  | 4.00  | 1.84  | 5.62  | 1.56  | 4.42  | 1.67  | 4.73  | 1.47  | 3.96  | 1.89  | 5.62  | 1.56  |
| F(2,140) = 4.98, p = 0.008 | | | | | | | | | | | | | | | |
| If PrEP is registered, it should be prescribed at STI clinics | 4.16  | 1.86  | 4.01  | 1.75  | 4.14  | 2.07  | 5.31  | 1.70  | 4.48  | 1.83  | 4.53  | 1.85  | 4.42  | 1.84  | 5.62  | 1.56  |
| F(2,140) = 2.86, p = 0.061 | | | | | | | | | | | | | | | |
| If PrEP is registered, it should be prescribed by HIV specialists | NA  |  |  |  |  |  |  |  | 3.91  | 1.97  | 4.03  | 2.06  | 3.73  | 1.87  | 3.91  | 1.97  |
| z = −0.66, p = 0.510 | | | | | | | | | | | | | | | |
| If PrEP is registered, it should be prescribed by general practitioners | NA  |  |  |  |  |  |  |  | 2.45  | 1.82  | 2.65  | 1.94  | 2.15  | 1.62  | 2.45  | 1.82  |
| z = −0.97, p = 0.333 | | | | | | | | | | | | | | | |
| If PrEP is registered, I would be willing to prescribe PrEP | NA  |  |  |  |  |  |  |  | 4.39  | 1.89  | 4.55  | 1.72  | 4.15  | 2.13  | 4.39  | 1.89  |
| z = −0.69, p = 0.489 | | | | | | | | | | | | | | | |
| Self-perceived knowledge of PrEP (7-point scale: 1 "very poor" to 7 "very good") | | | | | | | | | | | | | | | |
| Self-perceived knowledge of PrEP efficacy | 3.90  | 1.57  | 3.67  | 1.49  | 3.35  | 1.64  | 4.23  | 1.74  | 5.68  | 1.08  | 5.48  | 1.11  | 6.00  | 0.98  | 3.90  | 1.57  |
| F(2,140) = 2.91, p = 0.068 | | | | | | | | | | | | | | | |
| Self-perceived knowledge of PrEP side effects | 2.84  | 1.39  | 2.68  | 1.26  | 3.36  | 1.53  | 2.46  | 1.63  | 5.61  | 1.34  | 5.28  | 1.36  | 6.12  | 1.15  | 2.84  | 1.39  |
| H(2) = 6.21, p = 0.045 | | | | | | | | | | | | | | | |
| Self-perceived efficacy to inform clients about PrEP | 2.89  | 1.44  | 2.69  | 1.25  | 3.41  | 1.72  | 2.85  | 1.77  | 5.61  | 1.34  | 5.28  | 1.36  | 6.12  | 1.15  | 2.89  | 1.44  |
| H(2) = 4.35, p = 0.114 | | | | | | | | | | | | | | | |
| Self-perceived ability to identify key populations for PrEP | NA  |  |  |  |  |  |  |  | 5.02  | 1.33  | 4.95  | 1.38  | 5.12  | 1.28  | 5.02  | 1.33  |
| t(64) = 0.49, p = 0.625 | | | | | | | | | | | | | | | |
| Self-perceived capability of deciding to prescribe PrEP | NA  |  |  |  |  |  |  |  | 4.61  | 1.40  | 4.33  | 1.37  | 5.04  | 1.37  | 4.61  | 1.40  |
| t(64) = 0.27, p = 0.851 | | | | | | | | | | | | | | | |
| General beliefs about PrEP (7-point scale: 1 "completely disagree" to 7 "completely agree") | | | | | | | | | | | | | | | |
| It is unclear who has to pay for PrEP | 5.52  | 1.51  | 5.58  | 1.46  | 5.57  | 1.66  | 5.00  | 1.41  | 5.52  | 1.51  | 5.58  | 1.46  | 5.57  | 1.66  | 5.00  | 1.41  |
| H(2) = 2.41, p = 0.300 | | | | | | | | | | | | | | | |
| Taking PrEP is better than getting HIV | 5.27  | 1.49  | 5.09  | 1.59  | 5.51  | 1.26  | 5.85  | 1.14  | 5.27  | 1.49  | 5.09  | 1.59  | 5.51  | 1.26  | 5.85  | 1.14  |
| H(2) = 3.53, p = 0.171 | | | | | | | | | | | | | | | |

(Continued)
| Beliefs of Health-Care Professionals on PrEP | STI professionals | HIV specialists | STI professionals versus HIV specialists |
|-------------------------------------------|-------------------|----------------|-----------------------------------------|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
| Adherence to PrEP will be insufficient | 5.25 | 1.41 | 5.21 | 1.44 | 5.46 | 1.40 | 4.92 | 1.20 | H(2) = 2.55, p = 0.280 | NA |
| The role of the pharmaceutical companies in regard to PrEP is unclear | 4.97 | 1.43 | 5.06 | 1.47 | 4.65 | 1.25 | 5.23 | 1.59 | H(2) = 4.15, p = 0.126 | NA |
| The use of PrEP will lead to a decrease in condom use and an increase in STI | 4.87 | 1.21 | 5.07 | 1.08 | 4.66 | 1.34 | 4.02 | 1.32 | F(2,140) = 5.42, p = 0.005 | 5.13 | 1.34 | 5.10 | 1.37 | 5.17 | 1.32 | z = 0.27, p = 0.785 |
| PrEP is cheaper than lifelong HIV treatment | 4.86 | 1.49 | 4.72 | 1.48 | 5.05 | 1.54 | 5.31 | 1.38 | F(2,140) = 1.31, p = 0.274 | 3.88 | 0.89 | 3.87 | 0.91 | 3.88 | 0.89 | t(64) = 0.06, p = 0.954 |
| PrEP is an effective intervention to prevent HIV | 4.74 | 1.36 | 4.68 | 1.33 | 4.65 | 1.52 | 5.46 | 0.97 | H(2) = 3.67, p = 0.160 | 5.13 | 4.66 | 4.74 | 1.62 | 4.20 | 1.76 | 5.54 | 1.38 | H(2) = 6.99, p = 0.030 |
| PrEP prescription should be a part of routine care at STI clinics | 4.67 | 1.66 | 4.74 | 1.62 | 4.62 | 1.76 | 5.54 | 1.38 | H(2) = 6.99, p = 0.030 | NA |
| There is not enough knowledge yet about PrEP | 4.67 | 1.23 | 4.84 | 1.18 | 4.48 | 1.31 | 3.98 | 1.09 | F(2,140) = 3.45, p = 0.034 | NA |
| Costs of PrEP are a problem | 4.66 | 1.16 | 4.65 | 1.09 | 4.87 | 1.24 | 4.12 | 1.29 | F(2,140), p = 0.134 | NA |
| I would worry that some people have to use PrEP lifelong | 4.56 | 1.76 | 4.74 | 1.71 | 4.43 | 1.68 | 3.62 | 2.10 | H(2) = 4.08, p = 0.130 | NA |
| It is unethical to prescribe ART to healthy individuals | 4.31 | 1.49 | 4.44 | 1.48 | 4.24 | 1.42 | 3.62 | 1.69 | F(2,140) = 1.79, p = 0.170 | 4.64 | 1.72 | 4.85 | 1.41 | 4.31 | 2.09 | z = -0.91, p = 0.364 |
| PrEP is a good addition to prevention strategies | 4.27 | 1.07 | 4.28 | 1.01 | 4.04 | 1.15 | 4.80 | 1.14 | F(2,140) = 2.53, p = 0.083 | 4.23 | 1.59 | 4.38 | 1.39 | 4.00 | 1.85 | z = -0.68, p = 0.495 |
| The costs of PrEP will not outweigh the number of HIV infection prevented | 3.97 | 1.42 | 4.18 | 1.33 | 3.81 | 1.54 | 2.85 | 1.14 | F(2,140) = 5.69, p = 0.004 | NA |
| The STI clinic is not the right place for PrEP prescription | 3.72 | 1.12 | 3.75 | 1.12 | 3.72 | 1.16 | 3.57 | 1.15 | F(2,140) = 0.14, p = 0.869 | NA |
| The daily use of prevention strategies has already been tested | 3.35 | 1.58 | 3.51 | 1.51 | 2.78 | 1.62 | 3.85 | 1.72 | F(2,140) = 3.57, p = 0.031 | NA |
### Key Populations, Serodiscordant Couples, and Reimbursement of PrEP Costs

As shown in Figure 2, most participants believed the following groups to be eligible for PrEP: MSM who regularly get post-exposure prophylaxis after a sexual exposure (136/209, 65.1%), MSM who never use condoms with casual partners (134/209, 64.1%), and MSM or heterosexuals who have an HIV-positive steady partner with a detectable viral load (132/209, 63.2% and 112/209, 53.6%, respectively).

To prevent HIV transmission within serodiscordant couples, most HIV specialists preferred to treat only the HIV-positive partner (34/66, 51.5%) or to treat the HIV-positive partner while providing PrEP to the HIV-negative partner as long as the HIV-positive partner has a detectable viral load (26/66, 39.4%). A minority preferred only prescribing PrEP for the HIV-negative partner (2/66, 3.0%) or prescribing ART for the HIV-positive partner and PrEP for the HIV-negative partner without limited time frame (2/66, 3.0%), or just counseling (2/66, 3.0%). HIV physicians and nurses did not differ significantly in their preferences to prevent HIV transmission within serodiscordant couples.

As to PrEP costs, over half of STI professionals and HIV specialists (113/209, 54.1%) indicated that PrEP users should partially contribute, whereas 35.4% (74/209) indicated that PrEP users should pay all the costs; 5.7% (12/209) favored complete coverage by health insurance, 4.3% (9/209) were neutral, and 0.5% (1/209) indicated that the government should pay all the costs.

### DISCUSSION

This cross-sectional study on PrEP acceptability and its determinants found only moderate PrEP acceptability among STI professionals and HIV specialists. These moderate levels of acceptability are worrisome as they may impede smooth implementation of PrEP in the Netherlands. Facilitating factors toward PrEP acceptability in the Netherlands were the beliefs that PrEP is an effective intervention to prevent HIV, PrEP prescription should be a part of routine care at STI clinics, PrEP is a good addition to prevention strategies, and that taking PrEP is better than getting HIV. Beliefs forming barriers to PrEP implementation were the perceived potential decrease in condom use and the increase in STI prevalence, the high costs of PrEP, and the belief that it is unethical to prescribe ART to healthy individuals. Previous studies on PrEP-related beliefs of health-care professionals in developed countries have identified concerns regarding drug resistance, low adherence, a rise in STI, long-term toxicity, and lack of country-specific guidance (11–15). Some of these findings are now corroborated by our data for the Dutch context.

In order to increase the acceptability of PrEP implementation among health-care professionals in the Netherlands, the beliefs that may form barriers for PrEP implementation need to be addressed and beliefs that could facilitate PrEP implementation need to be more broadly communicated. Regarding the concerns around the anticipated decrease in condom use and the increase in STI in PrEP users, open-label studies showed mixed results.

---

**Table 2 (Continued)**

| Belief                                                                 | STI professionals | HIV specialists |
|-----------------------------------------------------------------------|-------------------|----------------|
| I'm worried about the long-term side effects of PrEP                  | NA                | NA             |
| PrEP will lead to an increase in HIV resistance                       | NA                | NA             |
| Non-normative HIV intervention (prison)                               | NA                | NA             |
| I'm worried about the short-term side effects of PrEP                 | NA                | NA             |
| ART, antiretroviral therapy; NA, not applicable, item not included in |                  |                |
TABLE 3 | Determinants of acceptability of PrEP implementation in the Netherlands among 143 STI professionals in the Netherlands (2015).

|                                | Univariable analyses |                      |                      | Multivariable analyses |                      |                      |
|--------------------------------|----------------------|----------------------|----------------------|------------------------|----------------------|----------------------|
|                                | **β** | **(95% CI)** | **p-value** | **β** | **(95% CI)** | **p-value** |
| Age                            |       |              |             |       |              |             |
| <40 years                      | Ref.  |           | 0.101      |       |              |             |
| 40–49 years                    | 0.20  | (−0.47: 0.88) |            |       |              |             |
| 50–59 years                    | 0.38  | (−0.33: 1.09) |            |       |              |             |
| ≥60 years                      | −0.03 | (−2.11: 0.05) |            |       |              |             |
| Gender                         |       |              |             |       |              |             |
| Male                           | Ref.  |           | 0.031      |       |              |             |
| Female                         | −0.74 | (−1.42: −0.07) |          |       |              |             |
| Profession                     |       |              |             |       |              |             |
| Nurse                          | Ref.  |           | 0.008      |       |              |             |
| Physician                      | −0.20 | (−0.83: 0.42) |            |       |              |             |
| Other                          | 1.41  | (0.45: 2.37)  |            |       |              |             |
| Location of STI clinic         |       |              |             |       |              |             |
| Large urban area               | Ref.  |           | 0.027      |       |              |             |
| Outside large urban area       | 0.63  | (0.07: 1.19)  |            |       |              |             |
| Length of employment within STI clinic |       |              |             |       |              |             |
| 0–4 years                      | Ref.  |           | 0.069      |       |              |             |
| 5–9 years                      | 0.14  | (−0.54: 0.82) |            |       |              |             |
| 10–14 years                    | −0.07 | (−0.83: 0.68) |            |       |              |             |
| ≥15 years                      | 1.11  | (0.22: 1.99)  |            |       |              |             |
| Questions about PrEP from clients in the previous 6 months |       |              |             |       |              |             |
| No                             | Ref.  |           | 0.201      |       |              |             |
| Yes                            | 0.36  | (−0.19: 0.92) |            |       |              |             |
| Self-perceived knowledge of PrEP (7-point scale: 1 "very poor" to 7 "very good") |       |              |             |       |              |             |
| Self-perceived knowledge of PrEP efficacy | 0.31  | (0.14: 0.48)  | <0.001     |       |              |             |
| Self-perceived knowledge of PrEP side effects | 0.31  | (0.11: 0.50)  | <0.002     |       |              |             |
| Self-perceived efficacy to inform clients about PrEP | 0.31  | (0.13: 0.50)  | <0.001     |       |              |             |
| Beliefs about the efficacy of PrEP |       |              |             |       |              |             |
| PrEP can reduce the risk of HIV by 100% | 1.55  | (−3.83: 0.73) |            |       |              |             |
| PrEP can significantly reduce the risk of HIV | −2.83 | (−5.44: −0.22) |          |       |              |             |
| Although PrEP reduces the risk of HIV, there is still a great risk of HIV transmission | −2.93 | (−5.35: −0.51) |          |       |              |             |
| I don't know                   |       |              |             |       |              |             |
| Beliefs about the frequency of PrEP side effects |       |              |             |       |              |             |
| Side effects are rare          | Ref.  |           | 0.006      |       |              |             |
| Side effects are sometimes reported | −1.09 | (−2.59: 0.41) |            |       |              |             |
| Side effects appear frequently | −1.98 | (−3.57: −0.40) |          |       |              |             |
| Knowledge about side effects is still scarce | −1.30 | (−2.92: 0.32) |            |       |              |             |
| I don't know                   | −2.04 | (−3.55: −0.53) |          |       |              |             |
| Beliefs about the severity of PrEP side effects |       |              |             |       |              |             |
| Side effects are often severe  | Ref.  |           | 0.084      |       |              |             |
| Side effects are often mild/non-severe | 1.13  | (−2.26: 2.53) |            |       |              |             |
| Knowledge about the severity of side effects is still scarce | 0.70  | (−0.83: 2.23) |            |       |              |             |
| I don't know                   | 0.42  | (−0.10: 1.84)  |            |       |              |             |
| General beliefs about PrEP (7-point scale: 1 "completely disagree" to 7 "completely agree") |       |              |             |       |              |             |
| It is unclear who has to pay for PrEP | −0.11 | (−0.30: 0.07)  | 0.222       |       |              |             |
| Taking PrEP is better than getting HIV | 0.59  | (0.43: 0.75)  | <0.001     | 0.15  | (0.02: 0.27)  | 0.020     |
| Adherence to PrEP will be insufficient | −0.36 | (−0.55: −0.17) | <0.001     |       |              |             |
| The role of the pharmaceutical companies in regard to PrEP is unclear | −0.25 | (−0.44: −0.06) | 0.011     |       |              |             |
| The use of PrEP will lead to a decrease in condom use and an increase in STI | −0.89 | (−1.06: −0.71) | <0.001     | −0.21 | (−0.42: −0.02) | 0.034     |
| PrEP is cheaper than lifelong HIV treatment | 0.42  | (0.25: 0.59)  | <0.001     |       |              |             |
| PrEP is an effective intervention to prevent HIV | 0.88  | (0.74: 1.02)  | <0.001     | 0.45  | (0.30: 0.61)  | <0.001     |
| PrEP prescription should be part of routine care at STI clinics | 0.65  | (0.52: 0.78)  | <0.001     | 0.17  | (0.04: 0.30)  | 0.013     |
| There is not enough knowledge yet about PrEP | −0.60 | (−0.81: −0.40) | <0.001     |       |              |             |
| Costs of PrEP are a problem | −1.01 | (−1.18: −0.84) | <0.001     | −0.28 | (−0.51: −0.03) | 0.019     |
| I would worry that some people have to use PrEP lifelong | −0.41 | (−0.55: −0.26) | <0.001     |       |              |             |
| It is unethical to prescribe ART to healthy individuals | −0.69 | (−0.84: −0.55) | <0.001     |       |              |             |
| PrEP is a good addition to prevention strategies | 1.13  | (0.95: 1.31)  | <0.001     |       |              |             |

(Continued)
The costs of PrEP will not outweigh the number of HIV infection prevented

-0.33 (−0.52; −0.14) 0.001

The STI clinic is not the right place for PrEP prescription

-0.71 (−0.93; −0.49) <0.001

Daily use of prevention strategies has already been tested

0.30 (0.13; 0.47) 0.001

| Determinants of acceptability of PrEP implementation in the Netherlands among 66 HIV specialists in the Netherlands (2015). |
|---------------------------------------------------------------|
| Demographic characteristics                                  |
| Age                                                          |
| <40 years Ref.                                               |
| 40–49 years −0.27 (−1.47; 0.93) 0.447                        |
| 50–59 years 0.10 (−1.17; 1.37)                               |
| ≥60 years −0.97 (−2.48; 0.54)                                 |
| Gender                                                       |
| Male Ref.                                                    |
| Female −0.10 (−0.94; 0.75)                                    |
| Profession                                                   |
| Nurse Ref.                                                   |
| Physician −0.76 (−1.59; 0.06) 0.070                           |
| Type of hospital                                             |
| Academic Ref.                                                |
| General 0.22 (−0.61; 1.05)                                    |
| Length of employment within hospital                         |
| 0–4 years Ref.                                               |
| 5–9 years 0.01 (−1.31; 1.34) 0.503                           |
| 10–14 years 0.02 (−1.27; 1.31)                               |
| ≥15 years −0.72 (2.06; 0.62)                                 |
| Number of HIV-positive patients in care                      |
| ≤250 Ref.                                                    |
| >250 0.23 (−0.62; 1.09)                                       |
| Questions about PrEP from patients in the previous 6 months  |
| No Ref.                                                      |
| Yes 0.12 (−0.40; 0.64)                                        |
| Ever prescribed PrEP                                         |
| No Ref.                                                      |
| Yes 0.61 (−0.94; 2.15)                                        |
| Self-perceived knowledge of PrEP (7-point scale: 1 "very poor" to 7 "very good") |
| Self-perceived knowledge of PrEP efficacy 0.26 (−0.12; 0.64) 0.175 |
| Self-perceived knowledge of PrEP side effects 0.05 (−0.26; 0.36) 0.742 |
| Self-perceived efficacy to identify target groups for PrEP 0.17 (−0.14; 0.48) 0.279 |
| Self-perceived capability of deciding to prescribe PrEP 0.12 (−0.18; 0.41) 0.431 |
| General beliefs about PrEP (7-point scale: 1 "completely disagree" to 7 "completely agree") |
| The use of PrEP will lead to a decrease in condom use and an increase in STI −0.69 (−0.95; 0.43) <0.001 |
| PrEP is an effective intervention to prevent HIV 1.09 (0.71; 1.47) <0.001 |
| It is unethical to prescribe ART to healthy individuals −0.54 (−0.75; −0.34) <0.001 |
| PrEP is a good addition to prevention strategies 0.68 (0.47; 0.88) <0.001 |
| I’m worried about the long-term side effects of PrEP −0.18 (−0.46; 0.09) 0.187 |
| PrEP will lead to an increase in HIV resistance −0.30 (−0.57; −0.03) 0.032 |
| Non-biomedical HIV interventions (i.e., behavioral) are better than PrEP −0.23 (−0.52; 0.06) 0.125 |
| I’m worried about the short-term side effects of PrEP 0.04 (−0.24; 0.31) 0.789 |

(16–21). If PrEP is implemented in the Netherlands, structured sexual-risk behavior counseling should be offered as the standard component of consultations (22). Addressing such concerns among health-care professionals and offering them tools to intervene on such topics among their clients may increase PrEP acceptability.
In our study and others across Europe (23), beliefs regarding the high costs of PrEP were likewise found to be a potential barrier for PrEP implementation. The costs of PrEP are indeed high and the implementation of PrEP therefore costly, but this barrier may be partly overcome if the study results that PrEP is most likely to be cost-effective and potentially even cost-saving are highlighted (10, 24, 25). In our study, over half of participants had the opinion that PrEP users need to contribute to the costs of PrEP. However, this was not further explored in relation to the amount that would need to be contributed and to the income. For those who cannot otherwise afford PrEP, the acceptability of public funding of costs was high in a study from the USA (26). The high costs have also
shown to be a potential barrier for the use of PrEP by potentially eligible candidates in the Netherlands (27, 28). The problem of cost combined with the lack of a reimbursement system clearly requires a solution to enable successful PrEP implementation in the Netherlands and probably in other countries lacking PrEP reimbursement programs. The recent introduction of significantly cheaper generic PrEP, also in the Netherlands (29), could provide a partial answer to the growing demand from PrEP in countries that lack a reimbursement system.

Although adherence to PrEP and long-term side effects were important concerns for participants, they were in our analysis not associated with the acceptability of PrEP implementation in the Netherlands. This finding could reflect current professional knowledge that (1) even with suboptimal levels of adherence, PrEP still yields a high level of protection and does not lead to drug resistance (16); and (2) possible long-term side effects are likely to be non-severe (7, 30, 31).

Among STI professionals, self-perceived knowledge of PrEP efficacy and side effects was significantly lower compared to HIV specialists, perhaps a result of their different educational and professional background. An alternative explanation is that data were collected earlier among STI professionals than among HIV specialists, and the interim period saw new research outcomes of PrEP studies (5–7), publication of the world health organization PrEP guidelines (1), and publicity for the start of the Amsterdam PrEP project (32). These developments could explain differences in knowledge between the two professional groups. It is important to improve PrEP knowledge among STI professionals, particularly as future PrEP programs are likely to be implemented at STI clinics. Many MSMs at risk for HIV and STI make use of free STI testing and treatment at Dutch STI clinics (33), and therefore PrEP counseling and provision could easily be incorporated into this setting. Our results also show that among HIV specialists, the implementation of PrEP is more acceptable at STI clinics than at HIV treatment centers. Although HIV specialists have more knowledge regarding ART, people wanting PrEP are not normally in need of such expensive and specialized hospital-based knowledge or care.

In regard to the use of daily or event-driven PrEP, our study showed no clear preference among the respondents. This may reflect the timing of the survey, which was taken just after the early interruption of two large European PrEP studies (one among daily and one among event-driven PrEP users) that both showed 86% reduction in the number of new HIV infections (5, 6).

As for key eligible populations, health-care professionals focused on MSM at a high risk of sexual acquisition of HIV and heterosexuals with an HIV-positive partner with a detectable viral load. These findings align with other studies (34, 35) and with recommendations for PrEP use in guidelines (1–3), indicating that health-care professionals in STI clinics and HIV treatment centers can correctly identify individuals eligible for PrEP.

Strengths of this study are its nationwide character, its use of both nurses and medical doctors from two different settings, and its application of measurement tools that were empirically generated through a qualitative elicitation process. However, some limitations need to be addressed. First, the number of completed questionnaires and the response rate were relatively low, as is common in survey-based research (36). Nevertheless, people from almost all invited STI clinics responded, as did more than one-third of HIV specialists. Second, to increase the response rate in the latter group, they were provided with a shorter questionnaire than was given to STI professionals, which made the comparison between the two groups more limited. Third, we did not include general practitioners in our study. As it may be likely that PrEP is implemented at general practitioners, PrEP acceptability should also be explored among this group of health-care professionals.

In conclusion, health-care professionals in STI clinics and HIV treatment centers in the Netherlands have only a moderate level of acceptability toward PrEP implementation, and PrEP knowledge among STI professionals is suboptimal. This may impede the smooth implementation of PrEP in the Netherlands. The high costs of PrEP, worries about a possible decrease in condom use and an increase in STI, and the belief that it is unethical to prescribe ART to healthy individuals were identified as influential barriers for PrEP implementation and need to be addressed in order to successfully implement PrEP in the future. Furthermore, it is important to increase PrEP knowledge in educational programs for STI professionals.

ETHICS STATEMENT

The questionnaire for health-care professionals was anonymous and did not request personal or sensitive data, and therefore approval by an ethics committee was not required, according to Dutch legislation.

AUTHOR CONTRIBUTIONS

Study concept and design: JB, EH, and UD. Data collection: JB, EH, FGD, and UD. Statistical analysis: JB and UD. Drafting of this manuscript: JB and EH. Interpretation of the data and critical revision of the manuscript: all authors.

ACKNOWLEDGMENTS

The authors wish to thank the following persons for their invaluable support: all participants of the study, Annebel Tahey for the dissemination of the survey at the STI outpatient clinic of the Public Health Service of Amsterdam, Ineke Stolte for help with designing the questionnaire, and Lucy Phillips for editing this manuscript.

FUNDING

This project received funding from the Public Health Service of Amsterdam Research and Development Funds (grant number 16-11).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fpubh.2018.00005/full#supplementary-material.
REFERENCES

1. World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV (2015). Available from: http://www.who.int/hiv/pub/guidelines/earlyrelease-2015/en/.

2. European AIDS Clinical Society (EACS). European Guidelines for Treatment of HIV-Positive Adults in Europe; Guidelines 9.0 (2015). Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html

3. US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 A Clinical Practice Guideline (2014). Available from: https://www.cdc.gov/hiv/risk/prep/index.html

4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 363(27):2587–99. doi:10.1056/NEJMoa1011208

5. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD); effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (2016) 387(10033):53–60. doi:10.1016/S0140-6736(15)00056-2

6. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all risk populations. AIDS (2016) 30(12):1973–83. doi:10.1097/QAD.0000000000001145

7. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness of pre-exposure prophylaxis for HIV-1 infection in the United States – 2014 A Clinical Practice Guideline

8. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all risk populations. AIDS (2016) 30(12):1973–83. doi:10.1097/QAD.0000000000001145

9. Nu.nl. PrEP Available in the Netherlands at 80% Lower Price (2017). Available from: https://www.nu.nl/gezondheid/4982345/hiv-preventiepil-prep-wordt-ruim-80-procent-goedkoper.html

10. Winston J, Chonchol M, Gallant J, Durr J, Canada RB, Liu H, et al. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomised clinical studies. HIV Clin Trials (2014) 15(6):231–45. doi:10.1310/1560-7917-ES.001.000000000004910

11. Puro V, Pulimuntem A, De Carlo G, Psallou P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis (2013) 13:217. doi:10.1186/1471-2334-13-217

12. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. Curr Opin AIDS (2016) 11(1):41–8. doi:10.1097/COH.000000000000206

13. Bil JP, Davidovich U, van der Veldt WM, Prins M, de Vries HJ, Sonder GJ, et al. What do Dutch MSM think of preexposure prophylaxis to prevent HIV-infection? A cross-sectional study. AIDS (2015) 29(8):955–64. doi:10.1097/QAD.0000000000000639

14. Chonchol M, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness of pre-exposure prophylaxis for HIV-1 infection in the United States – 2014 A Clinical Practice Guideline

15. Bil JP, van der Veldt WM, Prins M, de Vries HJ, Sonder GJ, et al. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomised clinical studies. HIV Clin Trials (2014) 15(6):231–45. doi:10.1310/1560-7917-ES.001.000000000004910

16. Puro V, Pulimuntem A, De Carlo G, Psallou P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis (2013) 13:217. doi:10.1186/1471-2334-13-217

17. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. The role of healthcare providers in the roll out of pre-exposure prophylaxis. Curr Opin AIDS (2016) 11(1):41–8. doi:10.1097/COH.000000000000206

18. Desai M, Gafos M, Dolling D, McCormack S, Nardone A; PROUD Study. Preexposure prophylaxis for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS (2013) 27(10):553–9. doi:10.1089/apc.2013.0173

19. Mannucci E, Nardone A, Rizzotto D, Spada A, Tarsitano R, Chiaravalloti E, et al. Pre-exposure prophylaxis for HIV infection in care settings: a qualitative study. AIDS Behav (2014) 18(9):1712–21. doi:10.1007/s10461-014-0839-3

20. Montano M, Dombrowsk J, Barbee A, Golden M, Khosropour C. Changes in sexually transmitted diseases physicians. JAMA Intern Med (2016) 176(1):75–84. doi:10.1001/jamainternmed.2015.4683

21. Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr (2016) 73(5):540–6. doi:10.1097/QAI.000000000000129

22. Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care (2016) 28(9):1154–8. doi:10.1080/09540121.2016.1153959

23. Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Diffusion of newer HIV prevention innovations: variable practices of frontline infectious diseases physicians. Clin Infect Dis (2016) 62(1):99–105. doi:10.1093/cid/civ736

24. BMJ. Planning and Conducting a Survey (2017). Available from: http://www.bmj.com/about-bmj/resources-readers/publications/planning-conducting-survey

Conflict of Interest Statement: The institute received financial reimbursement for the time served by EH on advisory boards of Gilead Sciences. For MP, the institute

Bil et al. - Beliefs of Health Care Professionals on PrEP

Frontiers in Public Health | www.frontiersin.org
February 2018 | Volume 6 | Article 5
13
received independent research support and speaker’s fees from Gilead, AbbVie, MSD, and Roche. For UD, the institute received independent research support from Gilead, AbbVie, MSD, and ViV. The Public Health Service of Amsterdam received PrEP medication from Gilead Sciences for the Amsterdam PrEP project and participated in a Gilead-sponsored study. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.